NO20072934L - Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt - Google Patents

Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt

Info

Publication number
NO20072934L
NO20072934L NO20072934A NO20072934A NO20072934L NO 20072934 L NO20072934 L NO 20072934L NO 20072934 A NO20072934 A NO 20072934A NO 20072934 A NO20072934 A NO 20072934A NO 20072934 L NO20072934 L NO 20072934L
Authority
NO
Norway
Prior art keywords
remodeling
treatment
heart failure
left ventricular
ranolazon
Prior art date
Application number
NO20072934A
Other languages
English (en)
Inventor
Brent Blackburn
Hani Sabbah
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20072934L publication Critical patent/NO20072934L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse vedrører en fremgangsmåte for å reversere venstre ventrikkelremodellering ved kombinert administrering av terapeutisk effektive mengder av ranolazin og minst ett samtidig remodellerende middel, som kan være en ACEinhibitor, en ARB eller en betablokker. Fremgangsmåten finner anvendelse i behandlingen av hjertesvikt. Denne oppfinnelsen vedrører også farmasøytiske forrnuleringer som er passende for slike kombinerte administreringer.
NO20072934A 2004-11-09 2007-06-08 Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt NO20072934L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62615404P 2004-11-09 2004-11-09
PCT/US2005/040824 WO2006053161A1 (en) 2004-11-09 2005-11-09 Use ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure

Publications (1)

Publication Number Publication Date
NO20072934L true NO20072934L (no) 2007-08-08

Family

ID=35892429

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072934A NO20072934L (no) 2004-11-09 2007-06-08 Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt

Country Status (15)

Country Link
US (2) US20060111361A1 (no)
EP (1) EP1809289A1 (no)
JP (1) JP2008519770A (no)
KR (1) KR20070084063A (no)
CN (1) CN101072562A (no)
AU (1) AU2005304421A1 (no)
BR (1) BRPI0517650A (no)
CA (1) CA2586840A1 (no)
IL (1) IL183056A0 (no)
MX (1) MX2007005367A (no)
NO (1) NO20072934L (no)
RU (1) RU2007121707A (no)
SG (1) SG156681A1 (no)
WO (1) WO2006053161A1 (no)
ZA (1) ZA200703697B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2486712C (en) * 2002-05-21 2012-01-03 Cv Therapeutics, Inc. Method of treating diabetes
JP5522663B2 (ja) * 2006-09-08 2014-06-18 カーディオポリマーズ， インコーポレイテッド 全体的な心臓のサイズ変更および再形成のための心筋内パターン形成
US20090012413A1 (en) * 2006-09-08 2009-01-08 Sabbah Hani N Cardiac patterning for improving diastolic function
CA2670651A1 (en) * 2006-12-21 2008-07-03 Cv Therapeutics, Inc. Reduction of cardiovascular symptoms
US20080193530A1 (en) * 2007-02-13 2008-08-14 Brent Blackburn Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
JP2010518170A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 冠微小血管疾患の処置のためのラノラジンの使用
EP2136780A1 (en) * 2007-02-13 2009-12-30 CV Therapeutics Inc. Use of ranolazine for the treatment of cardiovascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
AU2008239681B2 (en) * 2007-04-11 2013-10-03 Henry Ford Health System Cardiac repair, resizing and reshaping using the venous system of the heart
KR20100033490A (ko) * 2007-05-31 2010-03-30 질레드 팔로 알토 인코포레이티드 상승된 뇌-형 나트륨이뇨 펩티드에 대한 라놀라진
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
JP2011010865A (ja) 2009-06-30 2011-01-20 Ikaria Holdings Inc 肺高血圧の臨床的または超音波心臓検査上の証拠を伴う低酸素性呼吸器不全に罹った満期産およびほぼ満期産の新生児を治療する方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033967T2 (de) * 1989-06-23 2002-12-19 Syntex (U.S.A.) Llc, Palo Alto Ranolazin und verwandte Piperazine zur Behandlung von Schockzuständen
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6323226B1 (en) * 1999-10-19 2001-11-27 Texas Heart Institute Treatment of heart disease with cox-2 inhibitors
EP2033633A3 (en) * 2000-02-18 2009-07-08 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
AU2001277938A1 (en) * 2000-07-21 2002-02-05 Cv Therapeutics, Inc. Method for treating angina
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
AU2005304421A1 (en) 2006-05-18
WO2006053161A8 (en) 2006-09-14
EP1809289A1 (en) 2007-07-25
KR20070084063A (ko) 2007-08-24
RU2007121707A (ru) 2008-12-20
ZA200703697B (en) 2008-09-25
JP2008519770A (ja) 2008-06-12
CN101072562A (zh) 2007-11-14
SG156681A1 (en) 2009-11-26
US20090176772A1 (en) 2009-07-09
WO2006053161A1 (en) 2006-05-18
MX2007005367A (es) 2007-06-18
BRPI0517650A (pt) 2008-10-14
IL183056A0 (en) 2007-10-31
CA2586840A1 (en) 2006-05-18
US20060111361A1 (en) 2006-05-25

Similar Documents

Publication Publication Date Title
NO20072934L (no) Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
AR048588A1 (es) Uso de inhibidores de la fosfodiesterasa de tipo iii (pde iii) para la reduccion del tamano del corazon en mamiferos que padecen insuficiencia cardiaca
NO20082497L (no) Diarylureaer for behandling av pulmonal hypertensjon
NO20075400L (no) Fremgangsmater, sammensetninger og formuleringer for a forebygge eller lindre ugunstige virkninger i en pasient
NO20064584L (no) Tetrahydropyridoindolderivater
NO20080187L (no) Aspartylproteaseinhibitorer
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
ECSP11011030A (es) Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional.
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
NO20092569L (no) Inhibitorer av Akt-aktivitet
CL2011003266A1 (es) Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras.
NO20070933L (no) Indazoler anvendbare i behandling av kardiovaskulaere sykdommer
NO20091296L (no) Fremgangsmate for behandling av slag med trombolytisk middel
NO20070247L (no) Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase
WO2004009558A3 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
NO20072223L (no) Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse
NO20070139L (no) Heterosykliske derivater for behandling av hyperlipidemi og relaterte sykdommer
NO20055474L (no) Mediatorer av revers kolesteroltransport for behandling av hyperkolesterolemi
NO20083333L (no) Fremgangsmater for forbedring av farmakokinetikken til HIV-integraseinhibitorer
NO20053455L (no) Anvendelse av en kombinasjon inneholdende en ikke-nukleosid revers transkriptase inhibitor (NNRTI) med en inhibitor av cytokrom P450 sa som protease inhibitorer
AR119158A1 (es) Tratamientos de angioedema hereditario
NO20054216L (no) Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
CL2012000586A1 (es) Uso de al menos 20 mg de un aerosol de una solucion que comprende levofloxacina u ofloxacina y un cation bivalente o trivalente, para el tratamiento de una infeccion pulmonar en un paciente con fibrosis quistica.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application